Concepts (317)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 20 | 2024 | 75 | 3.970 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2024 | 677 | 3.720 |
Why?
|
| Prediabetic State | 8 | 2024 | 63 | 3.320 |
Why?
|
| Postmenopause | 28 | 2026 | 243 | 3.080 |
Why?
|
| Weight Loss | 10 | 2026 | 302 | 2.880 |
Why?
|
| Women's Health | 22 | 2026 | 178 | 2.150 |
Why?
|
| Humans | 103 | 2026 | 16832 | 1.810 |
Why?
|
| Female | 88 | 2026 | 12193 | 1.720 |
Why?
|
| Obesity | 14 | 2026 | 811 | 1.680 |
Why?
|
| Cholecalciferol | 10 | 2019 | 16 | 1.530 |
Why?
|
| Aged | 64 | 2026 | 5901 | 1.510 |
Why?
|
| Dietary Supplements | 15 | 2024 | 83 | 1.350 |
Why?
|
| Weight Reduction Programs | 2 | 2026 | 51 | 1.330 |
Why?
|
| Accidental Falls | 4 | 2015 | 49 | 1.320 |
Why?
|
| Risk Factors | 45 | 2026 | 3108 | 1.310 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 247 | 1.300 |
Why?
|
| Menopause | 6 | 2020 | 60 | 1.280 |
Why?
|
| Blood Glucose | 6 | 2024 | 315 | 1.230 |
Why?
|
| Fractures, Bone | 7 | 2022 | 92 | 1.220 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2026 | 35 | 1.220 |
Why?
|
| Vitamins | 7 | 2024 | 56 | 1.180 |
Why?
|
| Cognition | 7 | 2024 | 90 | 1.140 |
Why?
|
| Middle Aged | 53 | 2026 | 7515 | 1.130 |
Why?
|
| Mass Screening | 4 | 2022 | 670 | 1.120 |
Why?
|
| Osteoporotic Fractures | 7 | 2024 | 42 | 1.100 |
Why?
|
| Vitamin D Deficiency | 4 | 2015 | 23 | 1.070 |
Why?
|
| Cardiovascular Diseases | 8 | 2026 | 520 | 1.040 |
Why?
|
| Pediatric Obesity | 2 | 2026 | 101 | 1.030 |
Why?
|
| Prospective Studies | 27 | 2026 | 1186 | 1.020 |
Why?
|
| Calcium Carbonate | 6 | 2019 | 9 | 1.010 |
Why?
|
| Prenatal Care | 2 | 2020 | 123 | 1.010 |
Why?
|
| Body Mass Index | 20 | 2026 | 925 | 0.990 |
Why?
|
| Weight Gain | 8 | 2026 | 167 | 0.940 |
Why?
|
| Behavior Therapy | 4 | 2021 | 121 | 0.900 |
Why?
|
| Exercise Therapy | 3 | 2015 | 71 | 0.880 |
Why?
|
| Calcium, Dietary | 5 | 2017 | 28 | 0.870 |
Why?
|
| Metformin | 2 | 2022 | 49 | 0.830 |
Why?
|
| Estrogen Replacement Therapy | 7 | 2017 | 91 | 0.830 |
Why?
|
| Preconception Care | 3 | 2026 | 43 | 0.800 |
Why?
|
| Aging | 4 | 2015 | 146 | 0.780 |
Why?
|
| Cognitive Dysfunction | 3 | 2024 | 61 | 0.760 |
Why?
|
| Testosterone | 3 | 2014 | 19 | 0.750 |
Why?
|
| Hip Fractures | 6 | 2016 | 72 | 0.750 |
Why?
|
| Estradiol | 4 | 2014 | 20 | 0.740 |
Why?
|
| Calcium | 6 | 2020 | 27 | 0.730 |
Why?
|
| Adult | 22 | 2026 | 7255 | 0.720 |
Why?
|
| Male | 21 | 2026 | 9556 | 0.720 |
Why?
|
| Hot Flashes | 6 | 2020 | 37 | 0.720 |
Why?
|
| Estrogens | 5 | 2022 | 55 | 0.720 |
Why?
|
| Follow-Up Studies | 16 | 2026 | 1058 | 0.710 |
Why?
|
| Health Behavior | 6 | 2021 | 332 | 0.710 |
Why?
|
| Glycated Hemoglobin A | 3 | 2020 | 176 | 0.700 |
Why?
|
| Pregnancy | 11 | 2026 | 1555 | 0.690 |
Why?
|
| Dementia | 3 | 2020 | 137 | 0.680 |
Why?
|
| Aged, 80 and over | 18 | 2024 | 1887 | 0.680 |
Why?
|
| United States | 26 | 2026 | 3858 | 0.650 |
Why?
|
| Incidence | 15 | 2026 | 1229 | 0.650 |
Why?
|
| Anti-Obesity Agents | 2 | 2018 | 19 | 0.650 |
Why?
|
| Diet | 5 | 2024 | 349 | 0.620 |
Why?
|
| Sex Hormone-Binding Globulin | 5 | 2016 | 20 | 0.600 |
Why?
|
| Cohort Studies | 17 | 2024 | 2396 | 0.580 |
Why?
|
| Breast Density | 4 | 2022 | 24 | 0.570 |
Why?
|
| Obesity Management | 1 | 2018 | 4 | 0.560 |
Why?
|
| Pregnancy Complications | 2 | 2021 | 202 | 0.540 |
Why?
|
| Waist Circumference | 4 | 2026 | 34 | 0.540 |
Why?
|
| Primary Health Care | 2 | 2015 | 693 | 0.540 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2016 | 19 | 0.530 |
Why?
|
| Demography | 1 | 2017 | 89 | 0.520 |
Why?
|
| Menarche | 3 | 2026 | 26 | 0.520 |
Why?
|
| Femoral Fractures | 1 | 2017 | 23 | 0.510 |
Why?
|
| Sleep | 3 | 2024 | 54 | 0.500 |
Why?
|
| Life Style | 5 | 2026 | 305 | 0.500 |
Why?
|
| Menstruation | 1 | 2017 | 6 | 0.500 |
Why?
|
| Reproductive History | 1 | 2017 | 13 | 0.500 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 55 | 0.500 |
Why?
|
| Cross-Sectional Studies | 11 | 2024 | 1233 | 0.490 |
Why?
|
| Overweight | 6 | 2025 | 262 | 0.480 |
Why?
|
| Breast | 4 | 2019 | 66 | 0.480 |
Why?
|
| Residence Characteristics | 2 | 2017 | 244 | 0.460 |
Why?
|
| Treatment Outcome | 10 | 2021 | 1098 | 0.460 |
Why?
|
| Adolescent | 9 | 2026 | 3464 | 0.440 |
Why?
|
| Double-Blind Method | 10 | 2019 | 138 | 0.430 |
Why?
|
| Time Factors | 9 | 2019 | 989 | 0.430 |
Why?
|
| Exercise | 4 | 2025 | 513 | 0.420 |
Why?
|
| Body Composition | 3 | 2023 | 90 | 0.410 |
Why?
|
| Longitudinal Studies | 7 | 2026 | 653 | 0.410 |
Why?
|
| Diphosphonates | 1 | 2014 | 63 | 0.400 |
Why?
|
| Macular Degeneration | 4 | 2015 | 14 | 0.400 |
Why?
|
| Proportional Hazards Models | 12 | 2019 | 657 | 0.390 |
Why?
|
| Breast Neoplasms | 8 | 2022 | 913 | 0.390 |
Why?
|
| Bone Density | 6 | 2019 | 93 | 0.390 |
Why?
|
| Nonprescription Drugs | 1 | 2013 | 6 | 0.390 |
Why?
|
| Drug Compounding | 1 | 2013 | 5 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2023 | 317 | 0.370 |
Why?
|
| Young Adult | 7 | 2026 | 2456 | 0.370 |
Why?
|
| Neoplasms | 5 | 2019 | 447 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2017 | 305 | 0.330 |
Why?
|
| Surveys and Questionnaires | 8 | 2019 | 1204 | 0.330 |
Why?
|
| Age Factors | 7 | 2026 | 814 | 0.320 |
Why?
|
| Spinal Fractures | 3 | 2016 | 12 | 0.310 |
Why?
|
| Mortality | 2 | 2025 | 116 | 0.310 |
Why?
|
| Health Status Disparities | 1 | 2011 | 145 | 0.310 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 2019 | 42 | 0.290 |
Why?
|
| Preventive Health Services | 2 | 2022 | 142 | 0.290 |
Why?
|
| Child | 8 | 2026 | 2433 | 0.290 |
Why?
|
| Body Weight | 3 | 2020 | 197 | 0.290 |
Why?
|
| Infant, Newborn | 4 | 2026 | 828 | 0.280 |
Why?
|
| Self Report | 6 | 2025 | 248 | 0.280 |
Why?
|
| Risk Assessment | 6 | 2025 | 1047 | 0.270 |
Why?
|
| Sweating | 3 | 2017 | 8 | 0.260 |
Why?
|
| Retrospective Studies | 7 | 2025 | 2463 | 0.240 |
Why?
|
| Fetal Macrosomia | 3 | 2021 | 27 | 0.230 |
Why?
|
| Adiposity | 2 | 2023 | 69 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 107 | 0.220 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 103 | 0.220 |
Why?
|
| Sex Factors | 2 | 2024 | 560 | 0.220 |
Why?
|
| Emotions | 2 | 2015 | 32 | 0.220 |
Why?
|
| Fatigue | 2 | 2015 | 30 | 0.220 |
Why?
|
| Postpartum Period | 1 | 2025 | 89 | 0.220 |
Why?
|
| Sleep Wake Disorders | 2 | 2015 | 31 | 0.210 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2024 | 37 | 0.210 |
Why?
|
| Sex Characteristics | 1 | 2024 | 58 | 0.210 |
Why?
|
| Diet, Reducing | 3 | 2015 | 22 | 0.210 |
Why?
|
| Insulin Resistance | 1 | 2024 | 127 | 0.200 |
Why?
|
| Neuropsychological Tests | 3 | 2016 | 47 | 0.200 |
Why?
|
| Patient Compliance | 2 | 2016 | 262 | 0.200 |
Why?
|
| Carotenoids | 2 | 2014 | 25 | 0.200 |
Why?
|
| Patient Education as Topic | 1 | 2024 | 186 | 0.200 |
Why?
|
| Body Size | 2 | 2020 | 27 | 0.190 |
Why?
|
| Osteoporosis | 2 | 2014 | 73 | 0.180 |
Why?
|
| Feeding Behavior | 3 | 2024 | 161 | 0.180 |
Why?
|
| Infant | 1 | 2026 | 1212 | 0.180 |
Why?
|
| Premature Birth | 1 | 2023 | 133 | 0.170 |
Why?
|
| Advisory Committees | 1 | 2022 | 112 | 0.170 |
Why?
|
| Child, Preschool | 1 | 2026 | 1430 | 0.170 |
Why?
|
| Odds Ratio | 8 | 2017 | 569 | 0.170 |
Why?
|
| Geriatric Assessment | 2 | 2012 | 41 | 0.170 |
Why?
|
| Diabetes Mellitus | 2 | 2015 | 445 | 0.160 |
Why?
|
| Pregnancy Trimesters | 1 | 2020 | 27 | 0.160 |
Why?
|
| Glycemic Load | 1 | 2020 | 1 | 0.160 |
Why?
|
| Glycemic Index | 1 | 2020 | 17 | 0.150 |
Why?
|
| Hispanic Americans | 3 | 2021 | 350 | 0.150 |
Why?
|
| Anthropometry | 1 | 2020 | 54 | 0.150 |
Why?
|
| Sexual Maturation | 1 | 2019 | 7 | 0.150 |
Why?
|
| Adipose Tissue | 2 | 2018 | 63 | 0.150 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 94 | 0.150 |
Why?
|
| Counseling | 1 | 2021 | 170 | 0.150 |
Why?
|
| Contraceptives, Oral | 1 | 1999 | 22 | 0.150 |
Why?
|
| Parity | 1 | 2019 | 53 | 0.150 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 160 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2021 | 571 | 0.150 |
Why?
|
| Logistic Models | 3 | 2016 | 796 | 0.150 |
Why?
|
| Puberty | 1 | 2019 | 58 | 0.140 |
Why?
|
| Cholesterol, LDL | 2 | 2017 | 113 | 0.140 |
Why?
|
| Dietary Fats | 2 | 2016 | 88 | 0.140 |
Why?
|
| European Continental Ancestry Group | 3 | 2017 | 400 | 0.140 |
Why?
|
| Bias | 1 | 2018 | 90 | 0.140 |
Why?
|
| Breast Feeding | 1 | 2019 | 112 | 0.140 |
Why?
|
| Health Promotion | 1 | 2021 | 277 | 0.130 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2017 | 15 | 0.130 |
Why?
|
| Ovariectomy | 1 | 2017 | 7 | 0.130 |
Why?
|
| Hysterectomy | 1 | 2017 | 19 | 0.130 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2017 | 1 | 0.130 |
Why?
|
| Body Weights and Measures | 1 | 2017 | 11 | 0.130 |
Why?
|
| Biomarkers | 2 | 2015 | 284 | 0.130 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 42 | 0.130 |
Why?
|
| Endometrial Neoplasms | 1 | 2017 | 37 | 0.120 |
Why?
|
| Body Height | 2 | 2018 | 54 | 0.120 |
Why?
|
| Calcifediol | 2 | 2014 | 2 | 0.120 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2016 | 1 | 0.120 |
Why?
|
| Diet, Mediterranean | 1 | 2016 | 7 | 0.120 |
Why?
|
| Reproduction | 1 | 2016 | 10 | 0.120 |
Why?
|
| Pregnancy Rate | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cause of Death | 2 | 2019 | 171 | 0.120 |
Why?
|
| Memory Disorders | 1 | 2015 | 8 | 0.120 |
Why?
|
| Complement Factor I | 1 | 2015 | 1 | 0.120 |
Why?
|
| Age of Onset | 1 | 2015 | 66 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 79 | 0.110 |
Why?
|
| African Americans | 2 | 2017 | 394 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2016 | 130 | 0.110 |
Why?
|
| Institutionalization | 1 | 2015 | 1 | 0.110 |
Why?
|
| Homes for the Aged | 1 | 2015 | 4 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2020 | 702 | 0.110 |
Why?
|
| Vasomotor System | 1 | 2014 | 4 | 0.110 |
Why?
|
| Asymptomatic Diseases | 1 | 2015 | 23 | 0.110 |
Why?
|
| Insulin | 1 | 2015 | 181 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2014 | 6 | 0.110 |
Why?
|
| Risk | 2 | 2009 | 453 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 60 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 43 | 0.100 |
Why?
|
| Oregon | 1 | 2014 | 168 | 0.100 |
Why?
|
| Attitude to Health | 1 | 2015 | 142 | 0.100 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2016 | 155 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2014 | 60 | 0.100 |
Why?
|
| Hand Strength | 1 | 2013 | 12 | 0.100 |
Why?
|
| Memory | 1 | 2013 | 13 | 0.100 |
Why?
|
| Washington | 1 | 2014 | 376 | 0.100 |
Why?
|
| Atrial Fibrillation | 1 | 2015 | 173 | 0.100 |
Why?
|
| Cognition Disorders | 2 | 2012 | 30 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 189 | 0.100 |
Why?
|
| Asian Americans | 1 | 2014 | 146 | 0.100 |
Why?
|
| Retinal Pigments | 1 | 2013 | 2 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D 2 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2012 | 2 | 0.100 |
Why?
|
| Walking | 1 | 2013 | 82 | 0.090 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2012 | 4 | 0.090 |
Why?
|
| Delivery of Health Care | 1 | 2016 | 374 | 0.090 |
Why?
|
| Research Design | 2 | 2011 | 319 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2019 | 110 | 0.090 |
Why?
|
| Thyroid Diseases | 1 | 2012 | 2 | 0.090 |
Why?
|
| Thyroxine | 1 | 2012 | 6 | 0.090 |
Why?
|
| Thyroid Gland | 1 | 2012 | 6 | 0.090 |
Why?
|
| Thyrotropin | 1 | 2012 | 7 | 0.090 |
Why?
|
| Medication Adherence | 1 | 2014 | 235 | 0.090 |
Why?
|
| Prevalence | 4 | 2016 | 785 | 0.090 |
Why?
|
| Lactones | 1 | 2011 | 11 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2011 | 16 | 0.090 |
Why?
|
| Early Medical Intervention | 1 | 2011 | 11 | 0.090 |
Why?
|
| World Health Organization | 1 | 2011 | 10 | 0.090 |
Why?
|
| Models, Biological | 1 | 2011 | 26 | 0.090 |
Why?
|
| Diabetes, Gestational | 2 | 2021 | 330 | 0.090 |
Why?
|
| Absorptiometry, Photon | 2 | 2023 | 54 | 0.080 |
Why?
|
| Survival Rate | 1 | 2011 | 247 | 0.080 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 84 | 0.080 |
Why?
|
| Melanoma | 1 | 2011 | 35 | 0.080 |
Why?
|
| Antidepressive Agents | 1 | 2012 | 140 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 59 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 160 | 0.080 |
Why?
|
| Mammography | 2 | 2022 | 141 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 104 | 0.080 |
Why?
|
| Administration, Oral | 2 | 2020 | 81 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2017 | 995 | 0.070 |
Why?
|
| Depression | 1 | 2012 | 479 | 0.070 |
Why?
|
| Sleep Deprivation | 1 | 2007 | 3 | 0.060 |
Why?
|
| Stroke | 2 | 2019 | 297 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 105 | 0.060 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2026 | 8 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 635 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 410 | 0.060 |
Why?
|
| Genotype | 2 | 2015 | 198 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 489 | 0.050 |
Why?
|
| Prognosis | 2 | 2011 | 568 | 0.050 |
Why?
|
| Maternal Age | 1 | 2021 | 73 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2021 | 34 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2001 | 75 | 0.040 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2021 | 40 | 0.040 |
Why?
|
| Community Health Centers | 1 | 2021 | 58 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 45 | 0.040 |
Why?
|
| Dementia, Vascular | 1 | 2020 | 5 | 0.040 |
Why?
|
| Glucose Tolerance Test | 1 | 2020 | 108 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2020 | 58 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 31 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 1999 | 23 | 0.040 |
Why?
|
| Hip Joint | 1 | 2019 | 3 | 0.040 |
Why?
|
| Femur Neck | 1 | 2019 | 6 | 0.040 |
Why?
|
| Actigraphy | 1 | 2019 | 14 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 31 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 54 | 0.040 |
Why?
|
| Biopsy | 1 | 1999 | 74 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 76 | 0.040 |
Why?
|
| Probability | 1 | 2018 | 66 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 1999 | 322 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 215 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 6 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 6 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 9 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 2 | 0.030 |
Why?
|
| Protective Factors | 1 | 2017 | 28 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2017 | 41 | 0.030 |
Why?
|
| Intention | 1 | 2017 | 28 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 10 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 53 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2016 | 26 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 209 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 45 | 0.030 |
Why?
|
| Complement Factor B | 1 | 2015 | 1 | 0.030 |
Why?
|
| Complement C3 | 1 | 2015 | 2 | 0.030 |
Why?
|
| Complement Factor H | 1 | 2015 | 2 | 0.030 |
Why?
|
| Proteins | 1 | 2015 | 13 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2015 | 24 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2015 | 6 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 157 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Solubility | 1 | 2014 | 6 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 28 | 0.030 |
Why?
|
| Cholesterol | 1 | 2014 | 75 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2014 | 64 | 0.030 |
Why?
|
| Fetal Development | 1 | 2014 | 15 | 0.030 |
Why?
|
| beta-Carotene 15,15'-Monooxygenase | 1 | 2013 | 1 | 0.020 |
Why?
|
| Scavenger Receptors, Class B | 1 | 2013 | 1 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 516 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 278 | 0.020 |
Why?
|
| Urinary Calculi | 1 | 2012 | 1 | 0.020 |
Why?
|
| Cytochrome P450 Family 2 | 1 | 2012 | 2 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 23 | 0.020 |
Why?
|
| Sunlight | 1 | 2012 | 13 | 0.020 |
Why?
|
| Edible Grain | 1 | 2012 | 14 | 0.020 |
Why?
|
| Seasons | 1 | 2012 | 114 | 0.020 |
Why?
|
| Fruit | 1 | 2012 | 79 | 0.020 |
Why?
|
| Vegetables | 1 | 2012 | 88 | 0.020 |
Why?
|
| Thyroid Function Tests | 1 | 2012 | 2 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 2015 | 418 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2011 | 10 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 16 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2011 | 77 | 0.020 |
Why?
|
| Zeaxanthins | 1 | 2010 | 5 | 0.020 |
Why?
|
| Tocopherols | 1 | 2010 | 4 | 0.020 |
Why?
|
| Xanthophylls | 1 | 2010 | 6 | 0.020 |
Why?
|
| Lutein | 1 | 2010 | 7 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 8 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 52 | 0.020 |
Why?
|
| Motor Activity | 1 | 2012 | 196 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 255 | 0.020 |
Why?
|
| Mental Status Schedule | 1 | 2009 | 1 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 237 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 164 | 0.020 |
Why?
|
Concepts
(317)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(9)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->